Table of Content

Executive Summary

1 Technology Definition
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions

2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 CAR T-Cell Therapy: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview
4.1 Timeline of CAR T-Cell Therapy Development
4.2 CAR T-Cell Therapy Market and Growth Potential, 2019-2030
4.3 CAR T-Cell Therapy and Clinical Trials Landscape
4.3.1 Overview
4.3.2 Clinical Trials in China
4.3.3 Clinical Trials in Rest-of-the-World

5 Global CAR T-Cell Therapy Market, $Million, 2019-2030
5.1 Commercialized Therapeutics
5.1.1 Tisagenlecleucel (Kymriah)
5.1.2 Axicabtagene Ciloleucel (Yescarta)
5.1.3 Brexucabtagene Autoleucel (Tecartus)
5.2 Pipeline Therapeutics
5.2.1 BB2121 (Idecaptagene Cicleucel)
5.2.2 JCAR017 (Lisocabtagene Maraleucel)
5.2.3 KTE-C19 (Axicabtagene Ciloleucel)
5.2.4 CTL019 (Tisagenlecleucel)
5.2.5 JNJ-68284528
5.3 Impact of COVID-19 - CAR T-Cell Therapy
5.3.1 Impact of COVID-19 on Global CAR T-Cell Therapy Market Growth Rate
5.3.2 Clinical Trial Disruptions and Resumptions
5.3.3 COVID-19 Impact on Supply Chain of CAR T-Cell Therapy Market
5.3.4 Reduced Diagnosis of Cancer
5.3.5 Impact on Commercial Operations

6 CAR T-Cell Therapy Patent Landscape

7 Epidemiology of CAR T-Cell Therapy
7.1 Overview
7.2 CAR T-Cell Therapy Side-Effects
7.2.1 Cytokine Release Syndrome (CRS)
7.2.2 CAR T-Cell-Related Encephalopathy Syndrome (CRES)
7.2.3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
7.3 Management of CAR T-Cell Therapy Side-Effects

8 Industry Insights
8.1 Overview
8.2 Regulatory Scenario of CAR T-Cell Therapy
8.3 Legal Requirements and Frameworks in U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 Regulation of Cell Immunotherapy in China
8.5.2 Legal Requirements and Frameworks in Japan
8.6 Expedited Regulatory Designations Around the World
8.7 Pricing of CAR T-Cell Therapy
8.8 Reimbursement of CAR T-Cell Therapy

9 CAR T-Cell Therapy Development and Manufacturing
9.1 Overview
9.2 Challenges in CAR T-Cell Therapy
9.2.1 Therapy Approval
9.2.2 Manufacture Quality Control
9.2.3 Efficacy and Quality-Adjusted Life-Year (QALY) Assessment
9.2.4 Safety Assessment
9.2.5 Pricing and Patient Access
9.2.6 Reimbursement

10 Market Dynamics
10.1 Impact Analysis
10.2 Market Drivers
10.2.1 Rising Number of Patients with Hematologic Cancers
10.2.2 Dramatic Rise in Global CAR T-Cell Trials
10.2.3 Landmark Approvals of CAR T-Cell Therapies by USFDA and EMA
10.3 Market Restraints
10.3.1 High Treatment Cost of CAR T-Cell Therapy
10.3.2 Side-Effects of CAR T-Cell Therapy
10.4 Market Opportunities
10.4.1 Opportunities for Immunotherapy

11 Global CAR T-Cell Therapy Market (by Application)
11.1 Overview
11.2 Diffuse Large B-Cell Lymphoma (DLBCL)
11.3 Acute Lymphoblastic Leukemia (ALL)
11.4 Multiple Myeloma (MM)
11.5 Chronic Lymphocytic Leukemia (CLL)
11.6 Follicular Lymphoma (FL)
11.7 Mantle Cell Lymphoma (MCL)
11.8 Others

12 Global CAR T-Cell Therapy Market (by Target Antigen)
12.1 Overview
12.2 CD19/CD22
12.3 BCMA (B-Cell Maturation Antigen)
12.4 Other Antigens

13 Global CAR T-Cell Therapy Market (by Region)
13.1 Introduction
13.2 North America
13.2.1 U.S.
13.2.1.1 U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
13.2.2 Canada
13.2.2.1 Canada CAR T-Cell Therapy Market (by Application), 2019-2030
13.3 Europe
13.3.1 Germany
13.3.1.1 Germany CAR T-Cell Therapy Market (by Application), 2019-2030
13.3.2 U.K.
13.3.2.1 U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
13.3.3 France
13.3.3.1 France CAR T-Cell Therapy Market (by Application), 2019-2030
13.3.4 Italy
13.3.4.1 Italy CAR T-Cell Therapy Market (by Application), 2019-2030
13.3.5 Spain
13.3.5.1 Spain CAR T-Cell Therapy Market (by Application), 2019-2030
13.3.6 Rest-of-Europe
13.3.6.1 Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.2.1 Japan CAR T-Cell Therapy Market (by Application), 2019-2030
13.4.3 India
13.4.4 South Korea
13.4.5 Australia
13.4.5.1 Australia CAR T-Cell Therapy Market (by Application), 2019-2030
13.4.6 Rest-of-APAC
13.4.6.1 Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America
13.6 Rest-of-the-World

14 Competitive Landscape
14.1 Key Developments and Strategies
14.1.1 Overview
14.1.1.1 Regulatory and Legal Developments
14.1.1.2 Partnerships, Alliances, and Business Expansions
14.1.1.3 M&A Activities
14.1.1.4 Funding Activities
14.2 Market Share Analysis

15 Company Profiles
15.1 Overview
15.2 Amgen, Inc.
15.2.1 Company Overview
15.2.2 Role of Amgen, Inc. in Global CAR T-Cell Therapy Market
15.2.3 Financials
15.2.4 R&D Expenditure, 2017-2019
15.2.5 SWOT Analysis
15.3 Autolus Therapeutics plc
15.3.1 Company Overview
15.3.2 Role of Autolus Therapeutics plc in Global CAR T-Cell Therapy Market
15.3.3 Financials
15.3.4 R&D Expenditure, 2017-2019
15.3.5 SWOT Analysis
15.4 Bellicum Pharmaceuticals, Inc.
15.4.1 Company Overview
15.4.2 Role of Bellicum Pharmaceuticals, Inc. in Global CAR T-Cell Therapy Market
15.4.3 Financials
15.4.4 R&D Expenditure, 2017-2019
15.4.5 SWOT Analysis
15.5 Bluebird Bio Inc
15.5.1 Company Overview
15.5.2 Role of Bluebird Bio Inc in Global CAR T-Cell Therapy Market
15.5.3 Financials
15.5.4 R&D Expenditure, 2017-2019
15.5.5 SWOT Analysis
15.6 Bristol-Myers Squibb Company
15.6.1 Company Overview
15.6.2 Role of Bristol Myers Squibb Company in Global CAR T-Cell Therapy Market
15.6.3 Financials
15.6.4 R&D Expenditure, 2017-2019
15.6.5 SWOT Analysis
15.7 CARsgen Therapeutics, Ltd.
15.7.1 Company Overview
15.7.2 Role of CARsgen Therapeutics, Ltd. in Global CAR T-Cell Therapy Market
15.7.3 SWOT Analysis
15.8 Cartesian Therapeutics, Inc.
15.8.1 Company Overview
15.8.2 Role of Cartesian Therapeutics, Inc. in Global CAR T-Cell Therapy Market
15.8.3 SWOT Analysis
15.9 Cellectis S.A.
15.9.1 Company Overview
15.9.2 Role of Cellectis S.A. in Global CAR T-Cell Therapy Market
15.9.3 Financials
15.9.4 R&D Expenditure, 2017-2019
15.9.5 SWOT Analysis
15.1 Celyad Oncology SA
15.10.1 Company Overview
15.10.2 Role of Celyad Oncology SA in Global CAR T-Cell Therapy Market
15.10.3 Financials
15.10.4 R&D Expenditure, 2017-2019
15.10.5 SWOT Analysis
15.11 Fortress Biotech, Inc
15.11.1 Company Overview
15.11.2 Role of Fortress Biotech, Inc. in Global CAR T-Cell Therapy Market
15.11.3 Financials
15.11.4 R&D Expenditure, 2017-2019
15.11.5 SWOT Analysis
15.12 Janssen Pharmaceuticals, Inc.
15.12.1 Company Overview
15.12.2 Role of Janssen Pharmaceuticals, Inc in Global CAR T-Cell Therapy Market
15.12.3 Financials
15.12.4 R&D Expenditure, 2017-2019
15.12.5 SWOT Analysis
15.13 Kite Pharma, Inc (A Gilead Company)
15.13.1 Company Overview
15.13.2 Role of Kite Pharma, Inc in Global CAR T-Cell Therapy Market
15.13.3 Financials
15.13.4 R&D Expenditure, 2017-2019
15.13.5 SWOT Analysis
15.14 Legend Biotech Corporation
15.14.1 Company Overview
15.14.2 Role of Legend Biotech Corporation. in Global CAR T-Cell Therapy Market
15.14.3 SWOT Analysis
15.15 Novartis AG
15.15.1 Company Overview
15.15.2 Role of Novartis AG in Global CAR T-Cell Therapy Market
15.15.3 Financials
15.15.4 R&D Expenditure, 2017-2019
15.15.5 SWOT Analysis
15.16 Pfizer Inc.
15.16.1 Company Overview
15.16.2 Role of Pfizer Inc. in Global CAR T-Cell Therapy Market
15.16.3 Financials
15.16.4 R&D Expenditure, 2017-2019
15.16.5 SWOT Analysis
List of Tables
Table 1: Leading Players in Global CAR T-Cell Therapy Market
Table 8.1: History of Regulatory Activities and Tools Applied to Kymriah in U.S. and EU
Table 8.2: History of Regulatory Activities and Tools Applied to Yescarta in U.S. and EU
Table 8.3: Expedited Regulatory Designations Around the World
Table 10.1: Cytokine Release Syndrome (CRS) Grading Systems
Table 15.1: Amgen, Inc.: Pipeline Product Portfolio
Table 15.2: Autolus Therapeutics plc: Pipeline Product Portfolio
Table 15.3: Bellicum Pharmaceuticals, Inc.: Pipeline Product Portfolio
Table 15.4: Bluebird Bio Inc Company: Pipeline Product Portfolio
Table 15.5: Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 15.6: CARsgen Therapeutics, Ltd Company: Pipeline Product Portfolio
Table 15.7: Cartesian Therapeutics, Inc.: Pipeline Product Portfolio
Table 15.8: Celyad Oncology SA Company: Pipeline Product Portfolio
Table 15.9: Fortress Biotech, Inc: Pipeline Product Portfolio
Table 15.10: Janssen Pharmaceuticals, Inc Company: Pipeline Product Portfolio
Table 15.11: Kite Pharma, Inc: Pipeline Product Portfolio
Table 15.12: Legend Biotech Corporation, Company: Pipeline Product Portfolio
Table 15.13: Novartis AG: Pipeline Product Portfolio
Table 15.14: Pfizer Plc: Pipeline Product Portfolio
List of Figures
Figure 1: Global Prevalence of Hematologic Malignancies, 2018
Figure 2: Global Geriatric Population (by Age)
Figure 3: Global CAR T-Cell Therapy Clinical Trials (by Region)
Figure 4: Global CAR T-Cell Therapy Market
Figure 5: Global CAR T-Cell Therapy: Impact Analysis
Figure 6: Share of Key Developments and Strategies, June 2015-June 2020
Figure 7: Global CAR T-Cell Therapy Market (by Application), 2019 and 2030
Figure 8: Global CAR T-Cell Therapy Market (by Target Antigen), 2019 and 2030
Figure 9: Global CAR T-Cell Therapy Market (by Region), 2019 and 2030
Figure 2.1: Global CAR T-Cell Therapy Market Segmentation
Figure 3.1: Global CAR T-Cell Therapy Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Timeline of CAR T-Cell Therapy Development (Year-Wise Analysis)
Figure 4.2: CAR T-Cell Therapy Market Revenue (by Region), 2019 and 2030
Figure 4.3: Global CAR T-Cell Therapy Clinical Trials (by Region)
Figure 4.4: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials – U.S.
Figure 4.5: Global CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 4.6: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials – China
Figure 4.7: CAR T-Cell Therapy Clinical Trials in China (by Region)
Figure 4.8: CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 4.9: CAR T-Cell Therapy Clinical Trials – Rest-of-the-World (by Phase)
Figure 4.10: Global CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 5.1: Global CAR T-Cell Therapy Market (Kymriah – Product Revenue), 2019-2030
Figure 5.2: Global CAR T-Cell Therapy Market (Yescarta – Product Revenue), 2019-2030
Figure 5.3: Global CAR T-Cell Therapy Market (Tecartus – Product Revenue), 2020-2030
Figure 5.4: Global CAR T-Cell Therapy Market (Idecaptagene Cicleucel – Product Revenue)
Figure 5.5: Global CAR T-Cell Therapy Market (Lisocabtagene Maraleucel – Product Revenue)
Figure 5.6: Global CAR T-Cell Therapy Market (Axicabtagene Ciloleucel – Product Revenue)
Figure 5.7: Global CAR T-Cell Therapy Market (Tisagenlecleucel – Product Revenue)
Figure 5.8: Global CAR T-Cell Therapy Market (JNJ-68284528 – Product Revenue)
Figure 5.9: COVID-19 Status Globally
Figure 5.10: COVID-19 Progression Curve
Figure 5.11: Most Impacted Practices in CAR T-Cell Therapy
Figure 5.12: COVID-19 Impact on the CAR T-Cell Therapy Market
Figure 5.13: Impact of COVID-19 on Clinical Trials
Figure 5.14: Status of Clinical Trials
Figure 5.15: Disrupted Clinical Trials by Phase of Clinical Trial
Figure 5.16: Disrupted Clinical Trials by Therapy Area
Figure 5.17: Major Areas of Disruption
Figure 5.18: Diagnosis Rates of Various Cancer During Pandemic
Figure 5.19: Key Areas of Disruption in Commercial Operations
Figure 6.1: CAR T-Cell Therapy Patent Activity Ratio (by Region)
Figure 6.2: CAR T-Cell Therapy Patents (by Jurisdictions)
Figure 6.3: U.S. Patent Activity: Chimeric Antigen Receptor (Patents by Year)
Figure 7.1: Global Prevalence of Hematologic Malignancies , 2018
Figure 7.2: Estimated Incident Cases of Hematologic Malignancies in the U.S. (Total Population)
Figure 7.3: Estimated Incident Cases of Hematologic Malignancies in Canada (Total Population)
Figure 7.4: Estimated Incident Cases of Hematologic Malignancies in Germany (Total Population)
Figure 7.5: Estimated Incident Cases of Hematologic Malignancies in France (Total Population)
Figure 7.6: Estimated Incident Cases of Hematologic Malignancies in Italy (Total Population)
Figure 7.7: Estimated Incident Cases of Hematologic Malignancies in Spain (Total Population)
Figure 7.8: Estimated Incident Cases of Hematologic Malignancies in the U.K. (Total Population)
Figure 7.9: Estimated Incident Cases of Hematologic Malignancies in Japan (Total Population)
Figure 7.10: Estimated Incident Cases of Hematologic Malignancies in Australia (Total Population)
Figure 7.11: Grading System for Management of CAT T-Cell Toxicities
Figure 8.1: Regulatory Strategy for CAR T-Cell Therapy in U.S
Figure 8.2: Steps for Obtaining Marketing Authorization
Figure 8.3: USFDA Review Timeline
Figure 8.4: Regulatory Strategy for CAR T-Cell Therapy in EU
Figure 8.5: EMA Review Timeline
Figure 10.1: Global CAR T-Cell Therapy: Impact Analysis
Figure 10.2: Estimated Cases of Hematologic Malignancies in U.S., 2020
Figure 10.3: Estimated Number of Hematologic Malignancies, 2018 and 2030
Figure 10.4: Number of Clinical Trial, 2015-2020
Figure 10.5: Global CAR T-Cell Therapy Market, 2017-2019
Figure 10.6: CAR T-Cell Research Activity, 2018
Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 11.2: Global CAR T-Cell Therapy Market (for DLBCL), 2019-2030
Figure 11.3: Global CAR T-Cell Therapy Market (for ALL), 2019-2030
Figure 11.4: Global CAR T-Cell Therapy Market (for MM), 2019-2030
Figure 11.5: Global CAR T-Cell Therapy Market (for CLL), 2019-2030
Figure 11.6: Global CAR T-Cell Therapy Market (for FL), 2019-2030
Figure 11.7: Global CAR T-Cell Therapy Market (for MCL), 2019-2030
Figure 11.8: Global CAR T-Cell Therapy Market (for Others), 2019-2030
Figure 12.1: Global CAR T-Cell Therapy Market (by Target Antigen)
Figure 12.2: Global CAR T-Cell Therapy Market (for CD19/CD22), 2019-2030
Figure 12.3: Global CAR T-Cell Therapy Market (for BCMA), 2019-2030
Figure 12.4: Global CAR T-Cell Therapy Market (for Other Antigens), 2019-2030
Figure 13.1: Global CAR T-Cell Therapy Market (by Region)
Figure 13.2: Global CAR T-Cell Therapy Market (by Region), 2019-2030
Figure 13.3: North America CAR T-Cell Therapy Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: Revenue Contributions of Various Countries in North America, 2019 and 2030
Figure 13.6: U.S. CAR T-Cell Therapy Market, 2019-2030
Figure 13.7: U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.8: Canada CAR T-Cell Therapy Market, 2019-2030
Figure 13.9: Canada CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.10: Europe CAR T-Cell Therapy Market, 2019-2030
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Revenue Contributions of Various Countries in Europe, 2019 and 2030
Figure 13.13: Germany CAR T-Cell Therapy Market, 2019-2030
Figure 13.14: Germany CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.15: U.K. CAR T-Cell Therapy Market, 2019-2030
Figure 13.16: U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.17: France CAR T-Cell Therapy Market, 2019-2030
Figure 13.18: France CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.19: Italy CAR T-Cell Therapy Market, 2019-2030
Figure 13.20: Italy CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.21: Spain CAR T-Cell Therapy Market, 2019-2030
Figure 13.22: Spain CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.23: Rest-of-Europe CAR T-Cell Therapy Market, 2019-2030
Figure 13.24: Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.25: Asia-Pacific CAR T-Cell Therapy Market, 2019-2030
Figure 13.26: Asia-Pacific: Market Dynamics
Figure 13.27: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030
Figure 13.28: Japan CAR T-Cell Therapy Market, 2019-2030
Figure 13.29: Japan CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.30: Australia CAR T-Cell Therapy Market, 2019-2030
Figure 13.31: Australia CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.32: Rest-of-APAC CAR T-Cell Therapy Market, 2019-2030
Figure 13.33: Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.34: Latin America: Market Dynamics
Figure 13.35: RoW CAR T-cell therapy market, 2019-2030
Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
Figure 14.5: Market Share Analysis (by Company), 2018 and 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Amgen, Inc.: Overall Financials, 2017-2019
Figure 15.3: Amgen, Inc.: Sales (by Product), 2017-2019
Figure 15.4: Amgen, Inc.: Revenue (by Region), 2017-2019
Figure 15.5: Amgen, Inc.: R&D Expenditure, 2017-2019
Figure 15.6: Amgen, Inc.: SWOT Analysis
Figure 15.7: Autolus Therapeutics plc: Overall Financials, 2017-2019
Figure 15.8: Autolus Therapeutics plc: R&D Expenditure, 2017-2019
Figure 15.9: Autolus Therapeutics plc: SWOT Analysis
Figure 15.10: Bellicum Pharmaceuticals, Inc.: Overall Financials, 2017-2019
Figure 15.11: Bellicum Pharmaceuticals, Inc.: R&D Expenditure, 2017-2019
Figure 15.12: Bellicum Pharmaceuticals, Inc.: SWOT Analysis
Figure 15.13: Bluebird Bio Inc: Overall Financials, 2017-2019
Figure 15.14: Bluebird Bio Inc: R&D Expenditure, 2017-2019
Figure 15.15: Bluebird Bio Inc: SWOT Analysis
Figure 15.16: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 15.17: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 15.18: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 15.19: Bristol Myers Squibb Company: SWOT Analysis
Figure 15.20: CARsgen Therapeutics, Ltd.: SWOT Analysis
Figure 15.21: Cartesian Therapeutics, Inc: SWOT Analysis
Figure 15.22: Cellectis S.A.: Overall Financials, 2017-2019
Figure 15.23: Cellectis S.A.: Revenue (by Segment), 2017-2019
Figure 15.24: Cellectis S.A.: Revenue (by Region), 2017-2019
Figure 15.25: Cellectis S.A.: R&D Expenditure, 2017-2019
Figure 15.26: Cellectis S.A.: SWOT Analysis
Figure 15.27: Celyad Oncology SA: Overall Financials, 2017-2019
Figure 15.28: Celyad Oncology SA: Revenue (by Segment), 2018-2019
Figure 15.29: Celyad Oncology SA: R&D Expenditure, 2017-2019
Figure 15.30: Celyad Oncology SA: SWOT Analysis
Figure 15.31: Fortress Biotech, Inc: Overall Financials, 2017-2019
Figure 15.32: Fortress Biotech, Inc: Revenue (by Segment), 2017-2019
Figure 15.33: Fortress Biotech, Inc: R&D Expenditure, 2017-2019
Figure 15.34: Fortress Biotech, Inc: SWOT Analysis
Figure 15.35: Janssen Pharmaceuticals, Inc: Overall Financials, 2017-2019
Figure 15.36: Janssen Pharmaceuticals, Inc: Revenue (by Segment), 2017-2019
Figure 15.37: Janssen Pharmaceuticals, Inc: Revenue (by Region), 2017-2019
Figure 15.38: Janssen Pharmaceuticals, Inc: R&D Expenditure, 2017-2019
Figure 15.39: Janssen Pharmaceuticals, Inc: SWOT Analysis
Figure 15.40: Kite Pharma, Inc: Overall Product Portfolio
Figure 15.41: Kite Pharma, Inc: Overall Financials, 2017-2019
Figure 15.42: Kite Pharma, Inc: Revenue (by Segment), 2017-2019
Figure 15.43: Kite Pharma, Inc: Revenue (by Region), 2017-2019
Figure 15.44: Kite Pharma, Inc: R&D Expenditure, 2017-2019
Figure 15.45: Kite Pharma, Inc: SWOT Analysis
Figure 15.46: Legend Biotech Corporation: SWOT Analysis
Figure 15.47: Novartis AG: Overall Product Portfolio
Figure 15.48: Novartis AG: Overall Financials, 2017-2019
Figure 15.49: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.50: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.51: Novartis AG: R& D Expense, 2017-2019
Figure 15.52: Novartis AG: SWOT Analysis
Figure 15.53: Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.54: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.55: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.56: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.57: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.58: Pfizer Inc.: SWOT Analysis